विधियों की तुलना करें

	मेटा-विश्लेषणात्मक चरण I नैदानिक ​​परीक्षण	Network Meta-Analysis
क्षेत्र	महामारी विज्ञान	साक्ष्य संश्लेषण
परिवार	Process / pipeline	Process / pipeline
उद्भव वर्ष	2000s–2010s	2002
प्रवर्तक	Neuenschwander, Capkun-Niggli, Branson, Spiegelhalter and colleagues	Lumley (2002)
प्रकार	Bayesian meta-analytic dose-finding design	Method
मौलिक स्रोत	Neuenschwander, B., Capkun-Niggli, G., Branson, M., & Spiegelhalter, D. J. (2010). Summarizing historical information on controls in clinical trials. Clinical Trials, 7(1), 5–18.	Lumley, T. (2002). Network meta-analysis for indirect treatment comparisons. Statistics in Medicine, 21(16), 2313–2324.
उपनाम	meta-analytic dose-finding, MAP prior Phase I, MAPT design, Bayesian meta-analytic Phase I	Mixed Treatment Comparison, MTC, Indirect Comparison Meta-Analysis
संबंधित	1	1
सारांश	A meta-analytic Phase I clinical trial formally pools evidence from prior Phase I studies — using Bayesian or frequentist meta-analysis — to construct an informative prior (or summary estimate) for dose-toxicity relationships before or during a new first-in-human or early-phase study. The approach increases statistical efficiency, reduces the number of patients exposed to subtherapeutic or toxic doses, and accelerates dose selection by systematically leveraging all relevant historical dose-finding data.	Network meta-analysis (NMA) is a systematic method for comparing multiple interventions simultaneously within a single analytical framework, incorporating both direct evidence (head-to-head trials) and indirect evidence (comparisons via common comparators). First formalized by Lumley in 2002, NMA allows researchers to rank treatments and quantify comparative effectiveness even when some treatment pairs have never been directly studied.